Body mass index and incident cardiometabolic conditions in relation to obesity-related cancer risk: A population-based cohort study in Catalonia, Spain

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2023-09-28 DOI:10.1002/cam4.6603

Martina Recalde, Andrea Pistillo, Vivian Viallon, Emma Fontvieille, Talita Duarte-Salles, Heinz Freisling

{"title":"Body mass index and incident cardiometabolic conditions in relation to obesity-related cancer risk: A population-based cohort study in Catalonia, Spain","authors":"Martina Recalde, Andrea Pistillo, Vivian Viallon, Emma Fontvieille, Talita Duarte-Salles, Heinz Freisling","doi":"10.1002/cam4.6603","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>We investigated the association between body mass index (BMI) and obesity-related cancer risk among individuals with/without incident hypertension (HTN), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) and the joint associations of overweight/obesity (BMI ≥25 kg/m<sup>2</sup>) and each cardiometabolic condition with obesity-related cancer risk</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>We conducted a population-based cohort (<i>n</i> = 1,774,904 individuals aged ≥40 years and free of cancer and cardiometabolic conditions at baseline) study between 2010 and 2018 with electronic health records from Spain. Our main outcome measures were hazard ratios (HRs) for incident obesity-related cancers and relative excess risk due to interaction (RERI).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 38,082 individuals developed obesity-related cancers after a median of 8 years of follow-up. The positive association between BMI and obesity-related cancer risk was similar among individuals free of cardiometabolic conditions (hazard ratio, HR per 5 kg/m<sup>2</sup>: 1.08, 95% confidence interval, CI: 1.06–1.10) and with incident HTN (1.05, 1.01–1.08). The association among those with incident T2DM was null (0.98, 0.93–1.03). There was a positive additive interaction between overweight/obesity and CVD (relative excess risk due to interaction [RERI]: 0.19 [0.09, 0.30]), meaning that the combined association was 0.19 more than the sum of the individual associations. In contrast, a RERI of −0.24 (−0.28, −0.20) was observed for the combined association between overweight/obesity and T2DM.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Public health strategies to reduce overweight can help prevent cancer cases among the general population and individuals with incident HTN/CVD. Further, weight-loss interventions seem to lead to a greater cancer risk reduction among individuals with CVD.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"12 19","pages":"20188-20200"},"PeriodicalIF":2.9000,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6603","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.6603","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 1

Abstract

Background

We investigated the association between body mass index (BMI) and obesity-related cancer risk among individuals with/without incident hypertension (HTN), type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD) and the joint associations of overweight/obesity (BMI ≥25 kg/m²) and each cardiometabolic condition with obesity-related cancer risk

Methods

We conducted a population-based cohort (n = 1,774,904 individuals aged ≥40 years and free of cancer and cardiometabolic conditions at baseline) study between 2010 and 2018 with electronic health records from Spain. Our main outcome measures were hazard ratios (HRs) for incident obesity-related cancers and relative excess risk due to interaction (RERI).

Results

A total of 38,082 individuals developed obesity-related cancers after a median of 8 years of follow-up. The positive association between BMI and obesity-related cancer risk was similar among individuals free of cardiometabolic conditions (hazard ratio, HR per 5 kg/m²: 1.08, 95% confidence interval, CI: 1.06–1.10) and with incident HTN (1.05, 1.01–1.08). The association among those with incident T2DM was null (0.98, 0.93–1.03). There was a positive additive interaction between overweight/obesity and CVD (relative excess risk due to interaction [RERI]: 0.19 [0.09, 0.30]), meaning that the combined association was 0.19 more than the sum of the individual associations. In contrast, a RERI of −0.24 (−0.28, −0.20) was observed for the combined association between overweight/obesity and T2DM.

Conclusions

Public health strategies to reduce overweight can help prevent cancer cases among the general population and individuals with incident HTN/CVD. Further, weight-loss interventions seem to lead to a greater cancer risk reduction among individuals with CVD.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

体重指数和意外心脏代谢状况与肥胖相关癌症风险的关系：西班牙加泰罗尼亚的一项基于人群的队列研究。

背景：我们研究了有/无高血压（HTN）、2型糖尿病（T2DM）和心血管疾病（CVD）患者的体重指数（BMI）与肥胖相关癌症风险之间的相关性，以及超重/肥胖（BMI≥25 kg/m2）和每种与肥胖相关的癌症风险的心脏代谢状况。方法：我们进行了一项基于人群的队列研究（n = 年龄≥40岁的1774904人年，基线无癌症和心脏代谢状况）研究，并使用西班牙的电子健康记录。我们的主要结果指标是与肥胖相关的癌症事件的风险比（HR）和相互作用导致的相对过度风险（RERI）多年的随访。在没有心脏代谢疾病的个体中，BMI与肥胖相关的癌症风险之间的正相关相似（风险比，HR/5 kg/m2:1.08，95%置信区间，CI:1.06-1.10）和HTN事件（1.05，1.01-1.08）。与T2DM事件之间的相关性为零（0.98，0.93-1.03）。超重/肥胖与CVD之间存在正的加性相互作用（相互作用引起的相对超额风险[RERI]：0.19[0.09,0.30]），这意味着组合的关联比单个关联的总和多0.19。相反，观察到超重/肥胖与T2DM之间的综合相关性的RERI为-0.24（-0.28，-0.20）。结论：减少超重的公共卫生策略有助于预防普通人群和HTN/CVD患者中的癌症病例。此外，在心血管疾病患者中，减肥干预措施似乎能更大程度地降低癌症风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.